When the state of New Jersey decided to target physicians prescribing fentanyl sublingual spray (Subsys, INSYS Therapeutics) in an off-label manner, it not only made headlines but opened up an ethical debate that spanned medical specialties and state boundaries: Should drugs be used for off-label purposes? And what role should state agencies play in the regulation of such prescriptions, particularly when—as in the case of